Overton Brooks Research Corporation Inc

Study 1074: prominent pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes.

Csl behring, llc study 1214 with dr. Neeraj tandon as principal investigator(1) this pharmaceutical study is investigating the efficacy and safety of a drug called csl 112. (2) globally 10,584 participants have enrolled, but only one from thisvamc due to the trict inclusion/exclusion criteria. The long-term goal is to reduce future cardiovascular events in patients who have had a heart attack. (3) the one veteran enrolled locally has had no adverse events and is being followed per protocol